- Home
- RILY vs PBYI Comparison
RILY vs PBYI Comparison
Compare RILY & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RILY
- PBYI
- Stock Information
- Founded
- RILY 1973
- PBYI 2010
- Country
- RILY United States
- PBYI United States
- Employees
- RILY N/A
- PBYI N/A
- Industry
- RILY Investment Managers
- PBYI Biotechnology: Pharmaceutical Preparations
- Sector
- RILY Finance
- PBYI Health Care
- Exchange
- RILY Nasdaq
- PBYI Nasdaq
- Market Cap
- RILY 142.1M
- PBYI 145.3M
- IPO Year
- RILY 2007
- PBYI N/A
- Fundamental
- Price
- RILY $4.37
- PBYI $3.39
- Analyst Decision
- RILY
- PBYI Strong Buy
- Analyst Count
- RILY 0
- PBYI 1
- Target Price
- RILY N/A
- PBYI $7.00
- AVG Volume (30 Days)
- RILY 4.5M
- PBYI 481.2K
- Earning Date
- RILY 03-17-2025
- PBYI 05-01-2025
- Dividend Yield
- RILY 11.55%
- PBYI N/A
- EPS Growth
- RILY N/A
- PBYI 37.78
- EPS
- RILY N/A
- PBYI 0.62
- Revenue
- RILY $854,383,000.00
- PBYI $230,468,000.00
- Revenue This Year
- RILY N/A
- PBYI N/A
- Revenue Next Year
- RILY N/A
- PBYI N/A
- P/E Ratio
- RILY N/A
- PBYI $5.48
- Revenue Growth
- RILY N/A
- PBYI N/A
- 52 Week Low
- RILY $2.73
- PBYI $2.23
- 52 Week High
- RILY $40.09
- PBYI $6.06
- Technical
- Relative Strength Index (RSI)
- RILY 45.82
- PBYI 58.42
- Support Level
- RILY $4.70
- PBYI $3.27
- Resistance Level
- RILY $5.82
- PBYI $3.75
- Average True Range (ATR)
- RILY 1.07
- PBYI 0.23
- MACD
- RILY -0.04
- PBYI 0.05
- Stochastic Oscillator
- RILY 36.61
- PBYI 65.38
About RILY B. Riley Financial Inc.
B. Riley Financial Inc is a diversified financial services company. The company through its subsidiaries offers investment banking and financial services to corporate, institutional, and high-net-worth clients and also asset disposition, valuation and appraisal, and capital advisory services to retail, wholesale, institutional, lenders, capital providers, private equity investors, and professional services firms in United States, Canada, and Europe. It also provides internet access and subscription services. The reportable operating segments of the company include Capital Markets, Wealth Management, Financial Consulting, Auction and Liquidation, Communications segment, and Consumer products segment.
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes innovative products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.